Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 23, 2024$22.21
P/E Ratio
N/A
Market Cap
$1.2B
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Overview
Trading Information
Company